NAD Refers Salonpas Pain Patch Claims To FDA, FTC
This article was originally published in The Tan Sheet
Executive Summary
Hisamitsu America says Salonpas claims, which were challenged by Pfizer Consumer Healthcare, are consistent with FDA’s approval of the product’s NDA and its labeling.